Regeneron Pharmaceuticals, Inc. (REGN)
收市後：
| 前收市價 | 937.61 |
| 開市 | 926.94 |
| 買盤 | 956.86 x 100 |
| 賣出價 | 958.17 x 100 |
| 今日波幅 | 926.94 - 958.05 |
| 52 週波幅 | 684.81 - 998.33 |
| 成交量 | |
| 平均成交量 | 469,054 |
| 市值 | 105.448B |
| Beta 值 (5 年，每月) | 0.14 |
| 市盈率 (最近 12 個月) | 28.25 |
| 每股盈利 (最近 12 個月) | 33.88 |
| 業績公佈日 | 2024年8月01日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 1,053.08 |
Insider Monkey23 Most Profitable Stocks of the Last 12 Months
In this article, we discuss the 23 most profitable stocks of the last 12 months. If you want to skip our detailed analysis of these stocks, go directly to 5 Most Profitable Stocks of the Last 12 Months. The United States stock market has come a long way since the turn of the millennium more […]
Insider MonkeyRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript May 2, 2024 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $9.55 EPS, expectations were $10.17. Regeneron Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to […]
Investor's Business DailyRegeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.
